Adicet Bio, Inc. (NASDAQ:ACET – Get Free Report) was the target of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 4,620,000 shares, a decrease of 13.5% from the July 15th total of 5,340,000 shares. Based on an average trading volume of 1,040,000 shares, the short-interest ratio is currently 4.4 days.
Adicet Bio Stock Up 7.0 %
ACET stock opened at $1.53 on Monday. Adicet Bio has a 52-week low of $1.05 and a 52-week high of $3.77. The firm has a market cap of $126.07 million, a P/E ratio of -0.52 and a beta of 1.80. The company’s 50-day simple moving average is $1.34 and its 200-day simple moving average is $1.84.
Adicet Bio (NASDAQ:ACET – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.03. On average, analysts anticipate that Adicet Bio will post -1.37 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on ACET
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. AQR Capital Management LLC increased its holdings in Adicet Bio by 478.3% in the 2nd quarter. AQR Capital Management LLC now owns 136,765 shares of the company’s stock worth $165,000 after acquiring an additional 113,115 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Adicet Bio in the second quarter valued at about $62,000. Squarepoint Ops LLC increased its stake in shares of Adicet Bio by 2,728.8% during the second quarter. Squarepoint Ops LLC now owns 362,230 shares of the company’s stock worth $438,000 after purchasing an additional 349,425 shares in the last quarter. Cubist Systematic Strategies LLC raised its position in shares of Adicet Bio by 790.1% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 409,049 shares of the company’s stock worth $495,000 after purchasing an additional 363,095 shares during the last quarter. Finally, Point72 DIFC Ltd lifted its stake in Adicet Bio by 77.5% in the 2nd quarter. Point72 DIFC Ltd now owns 33,441 shares of the company’s stock valued at $40,000 after buying an additional 14,596 shares in the last quarter. Hedge funds and other institutional investors own 83.89% of the company’s stock.
About Adicet Bio
Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Further Reading
- Five stocks we like better than Adicet Bio
- How to Choose Top Rated Stocks
- This Small Cap Wealth Management Stock Could Provide Big Returns
- P/E Ratio Calculation: How to Assess Stocks
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 8/12 – 8/16
Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.com's FREE daily email newsletter.